Zimmer Biomet (NYSE:ZBH – Get Free Report) posted its earnings results on Wednesday. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02, FiscalAI reports. The business had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 earnings per share.
Here are the key takeaways from Zimmer Biomet’s conference call:
- Zimmer Biomet reported 3.7% constant-currency sales growth, with hips up 7%, S.E.T. up 7.1%, and technology, data, bone cement, and surgical up 13%. The company said two-thirds of its portfolio grew at upper-single-digit or double-digit rates.
- The company raised its 2026 organic constant-currency sales growth outlook to 3%–3.5% and adjusted EPS guidance to $8.50–$8.60. It cited stronger-than-expected performance and expects full-year free cash flow to grow 9%–11%.
- Knee sales declined 2.6% in constant currency, amid U.S. sales-force transition and competitive pressure, with China also weighing on results. Management expects near-term pressure to continue and acknowledged the transition’s final stage carries higher risk.
- Zimmer Biomet plans to submit Monogram’s 510(k) application soon and expects a potential launch in the first half of 2027, ahead of its prior timeline; the timing remains subject to FDA approval. Management views the system as a potential growth catalyst alongside its existing robotics offerings.
- Third-quarter adjusted EPS was flat at $1.90, while adjusted operating margin fell 140 basis points to 25.1%, reflecting investment in the U.S. commercial organization and higher manufacturing costs.
Zimmer Biomet Price Performance
NYSE ZBH traded up $14.38 on Wednesday, reaching $111.44. The company’s stock had a trading volume of 3,206,353 shares, compared to its average volume of 2,245,582. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $112.55. The stock has a market cap of $21.26 billion, a PE ratio of 27.09, a PEG ratio of 2.34 and a beta of 0.50. The firm’s 50 day moving average is $94.71 and its two-hundred day moving average is $91.78. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.
Zimmer Biomet Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a $0.24 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet’s payout ratio is 23.36%.
Analyst Upgrades and Downgrades
ZBH has been the subject of several recent research reports. Citigroup reaffirmed a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, October 5th. Sanford C. Bernstein increased their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Canaccord Genuity Group boosted their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a “hold” rating in a research report on Monday, August 10th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Finally, Zacks Research upgraded Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 25th. Seven investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $104.47.
Check Out Our Latest Stock Analysis on ZBH
Trending Headlines about Zimmer Biomet
Here are the key news stories impacting Zimmer Biomet this week:
- Positive Sentiment: Third-quarter revenue was $2.063 billion, up 3.1% year over year, while adjusted earnings of $1.90 per share beat analyst estimates. Zimmer Biomet Announces Third Quarter 2026 Financial Results
- Positive Sentiment: Zimmer Biomet raised its full-year 2026 outlook. Strong Hips and S.E.T. sales helped offset softness elsewhere, supporting investor optimism and the stock’s move to a 52-week high. Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
- Neutral Sentiment: Adjusted EPS was unchanged from a year earlier. The reported diluted EPS figure was $1.00, down 13.8%, reflecting a less favorable picture on a GAAP basis than the adjusted result. Zimmer Biomet Announces Third Quarter 2026 Financial Results
- Negative Sentiment: Knee-market weakness and margin pressure remain headwinds, partially offsetting growth in Hips and S.E.T. Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, ’26 View Up
Insider Buying and Selling at Zimmer Biomet
In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the sale, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This trade represents a 4.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The SEC filing for this sale provides additional information. Company insiders own 1.28% of the company’s stock.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.
The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.
Read More
- Five stocks we like better than Zimmer Biomet
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
